diagnosis
Diagnosis should be made on the basis of a surgical specimen/ excisional lymph node or extranodal tissue biopsy providing enough material for formalin-fixed samples. Core biopsies may be appropriate as the only diagnostic test in the rare patients requiring emergency treatment. Immunohistochemistry is mandatory with description of minimal antibody panel results (CD45, CD20 and CD3). The determination of CD10, BCL-2 and MUM1 expression for differentiation of germinal center derivation (GCB) or activated B-cell (ABC) type is optional. The collection of fresh frozen material for molecular characterization is recommended although gene expression profiling remains investigational. To ensure adequate quality, processing by an experienced pathology institute has to be guaranteed. treatment Treatment strategies should be stratified according to age, ageadapted IPI and feasibility of dose-intensified approaches. Whenever available, the inclusion in a clinical trial should be proposed.
In cases with high tumor load, special precautions (e.g. corticosteroid pre-phase) are required to avoid tumor lysis syndrome. Dose reductions due to hematological toxicity should be avoided. Febrile neutropenia justifies prophylactic use of hematopoietic growth factors in patients treated with curative intent.
young low-risk patients (aaIPI £1)
Six to eight cycles of combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) combined with eight doses of rituximab given every 21 days is the current standard for CD20+ BLBCL of all stages [I, A]. Consolidation by radioimmunotherapy to initial sites has no proven benefit [I, A].
young high-risk patients (aaIPI ‡2)
There is no current standard with sufficient efficacy. Thus, especially this patient population should be treated preferably in clinical trials. However, six to eight cycles of combination chemotherapy with CHOP treatment combined with eight doses of rituximab given every 14-21 days are most frequently applied. Dose-intensive regimens and high-dose chemotherapy with stem-cell transplantation, as part of first-line therapy, remain experimental. Central nervous system relapse prophylaxis is recommended in high-risk patients. Consolidation by radiotherapy to sites of bulky disease has not proved of benefit [III, C].
patients older than 60 years
Eight cycles of combination chemotherapy with CHOP treatment combined with eight doses of rituximab given every 21 days is the current standard [I, A]. If rituximab (R)-CHOP is given every 14 days, six cycles are sufficient.
response evaluation
Abnormal radiological tests at baseline should be repeated after three to four cycles and after the last cycle of treatment. Bone marrow aspirate/biopsy should be repeated only at the end of treatment if initially involved.
PET, when positive at baseline, is part of the updated response criteria. However, in case of therapeutic consequences a histological confirmation of PET positivity is strongly recommended. PET performed after one to four cycles of treatment is predictive of clinical outcome but should be restricted to clinical trials. 
follow-up

relapsed and refractory DLBCL incidence
Overall, >30% of DLBCL will ultimately relapse. The incidence in the European Union is therefore estimated to be around 2/ 100 000/year. diagnosis Histological verification should be obtained whenever possible, and is mandatory in relapses >12 months after the initial diagnosis, especially in order to ensure CD20 positivity. Imageguided core biopsy may be appropriate in this context.
staging and risk assessment
Patients still amenable to curative therapy should have the same examinations as at initial phase.
treatment
The following recommendations apply to patients with adequate, rituximab-associated anthracycline-containing firstline therapy. Phase II studies combining rituximab with salvage or high-dose chemotherapy clearly suggest superior response and disease-free survival over chemotherapy alone [II, A] , but the advantage after first-line therapy containing rituximab is not established. In suitable patients with adequate performance status (no major organ dysfunction, age <65 years) salvage regimen followed by high-dose treatment with stem-cell support in responsive patients is recommended [II, A] . Any of the published salvage regimens such as R-DHAP, R-ESHAP, R-ICE, etc. may be adequate until results of comparative trials are known. The choice of the high-dose regimen depends on local experience with BEAM (carmustine, etoposide, cytosine-arabinoside and melphalan) being most frequently used. Additional involved-field radiation or iceberg radiation may be used especially in the few cases with limited-stage disease, but has been never evaluated in controlled trials.
Patients not suitable for high-dose therapy may be treated with the same or other salvage regimens (e.g. R-IMVP16, R-GEMOX, etc.) and may be combined with involved-field radiotherapy.
response evaluation
Response criteria are identical to those of first-line treatment evaluation. An evaluation should be performed after three to four cycles of salvage regimen (before high-dose treatment) and after the end of all therapy. Results of PET before high-dose treatment are correlated to clinical outcome.
follow-up
Follow-up of patients in second response could be the same as first response. 
